Nasdaq

Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies

SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
Nasdaq

Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.

SALT LAKE CITY, Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...
Morningstar

Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025

SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
Seeking Alpha

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY, ...
Morningstar

Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform

Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx's existing and future AI initiatives SALT LAKE CITY, Nov. 3, 2025 /PRNewswire/ ...